Skip to Main Content

Paper Details

Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.
Clin Cancer Res
80
2018
Anti-CTLA4, BTLA, CD8, CTLA4, IL9, Metastatic Melanoma, Patients, TIL, TIL ACT, anti-CTLA4, anti-PD1, metastatic melanoma, patients, tumor, tumor-infiltrating lymphocytes
Author NameAffiliation
Kenneth R HessThe University of Texas MDACC
Kenneth R HessThe University of Texas MDACC
Michael A DaviesThe University of Texas MD Anderson Cancer Center (MDACC)
Michael A DaviesThe University of Texas MD Anderson Cancer Center (MDACC)
Hussein A TawbiThe University of Texas MD Anderson Cancer Center (MDACC)
Jeffrey E GershenwaldThe University of Texas MDACC
Jeffrey E GershenwaldThe University of Texas MDACC
Janice N CormierThe University of Texas MDACC
Jennifer A WargoThe University of Texas MDACC
Jennifer A WargoThe University of Texas MDACC
Rameen BeroukhimBroad Institute of Harvard and MIT
Rameen BeroukhimDana-Farber Cancer Institute
Rameen BeroukhimDana-Farber Cancer Institute
  • 1 - 13

Datasets

Release 1.2